Valuation : Charles River Laboratories International, Inc.

Market Cap 1.38TCr 1.18TCr 1.11TCr 1.02TCr 1.9TCr 1,30300Cr 1.91TCr 13TCr 5.11TCr 67TCr 5.17TCr 5.06TCr 2,12500Cr P/E 2026 *
77.2x
P/E 2027 * 33.1x
Enterprise Value 1.59TCr 1.37TCr 1.28TCr 1.17TCr 2.19TCr 1,50200Cr 2.2TCr 15TCr 5.89TCr 77TCr 5.97TCr 5.84TCr 2,45100Cr EV / Sales 2026 *
4.06x
EV / Sales 2027 * 3.85x
Free-Float
95.58%
Yield 2026 *
-
Yield 2027 * -
06:54pm Charles River Laboratories International Implements Endosafe Cartridge Technology Automated Manufacturing Suite CI
21/08 Charles River Laboratories International Insider Sold Shares Worth $599,711, According to a Recent SEC Filing MT
20/08 Charles River, Medigen Partner on Multivalent Enterovirus Vaccine MT
20/08 Charles River Laboratories International, Inc. and Medigen Vaccine Biologics Corp. Collaborate to Advance New Vaccine Development Programs Through Next Generation Sequencing CI
14/08 Charles River Laboratories International Insider Sold Shares Worth $1,038,657, According to a Recent SEC Filing MT
10/08 TD Cowen Adjusts PT on Charles River Laboratories International to $300 From $235, Maintains Buy Rating MT
10/08 Rothschild & Co Redburn Adjusts PT on Charles River Laboratories International to $318 From $241, Maintains Buy Rating MT
07/08 Charles River Laboratories International Insider Sold Shares Worth $1,327,098, According to a Recent SEC Filing MT
06/08 Barclays Adjusts Price Target on Charles River Laboratories International to $300 From $220 MT
06/08 RBC Adjusts PT on Charles River Laboratories International to $282 From $215, Keeps Outperform Rating MT
06/08 Deutsche Bank Adjusts Charles River Laboratories International PT to $300 From $260, Maintains Buy Rating MT
06/08 Analyst recommendations: AppLovin, Emerson Electric, Roblox, Flutter Entertainment, HubSpot... Zonebourse
06/08 JPMorgan Upgrades Charles River Laboratories International to Overweight From Neutral, Adjusts PT to $310 From $180 MT

Last Transcript : Charles River Laboratories International, Inc.

1 day-2.06%
1 week+2.46%
Current month+1.32%
1 month+9.82%
3 months+61.91%
6 months+70.85%
Current year+47.69%
1 week 243.4
Extreme 243.4
253.8
1 month 231.1
Extreme 231.1
255.7
Current year 127.95
Extreme 127.95
255.7
1 year 124.25
Extreme 124.25
255.7
3 years 87.7
Extreme 87.7
255.7
5 years 87.7
Extreme 87.7
388
10 years 59.83
Extreme 59.829
388
Manager TitleAgeSince
Chief Executive Officer 56 05/05/2026
Director of Finance/CFO 58 06/04/2026
Chief Tech/Sci/R&D Officer 45 12/01/2026
Director TitleAgeSince
Chairman 75 01/01/2000
Director/Board Member 56 05/05/2026
Chairman 69 05/05/2026
Change 5-day change 1-year change 3-year change Capi.($)
-2.06%+2.46% - - 1.38TCr
-0.29%-3.43%-2.14%+15.34% 4.84TCr
+0.75%+0.23%+412.32%+554.92% 4.5TCr
-2.50%+0.77%+38.77%+21.97% 4.41TCr
-3.46%-3.56%-0.17%+79.55% 4.07TCr
-0.96%-1.38%+15.75%+45.91% 3.32TCr
-0.58%+2.94% - - 1.78TCr
-0.47%+1.11%+19.84%+117.51% 1.65TCr
-0.47%-0.39%+11.51%+31.56% 1.45TCr
-2.14%-0.52%+73.38%+40.62% 1.38TCr
Average -1.16%+0.29%+71.16%+113.42% 3.04TCr
Weighted average by Cap. -1.16%-0.02%+86.61%+134.33%

Financials

2026 *2027 *
Net sales 391.1Cr 336.35Cr 316.35Cr 288.78Cr 540.08Cr 37TCr 541.83Cr 3.75TCr 1.45TCr 19TCr 1.47TCr 1.44TCr 60TCr 400.08Cr 344.07Cr 323.61Cr 295.4Cr 552.48Cr 38TCr 554.27Cr 3.84TCr 1.48TCr 19TCr 1.5TCr 1.47TCr 62TCr
Net income 16Cr 14Cr 13Cr 12Cr 22Cr 1.54TCr 22Cr 155.7Cr 60Cr 786.29Cr 61Cr 60Cr 2.5TCr 43Cr 37Cr 35Cr 32Cr 59Cr 4.04TCr 59Cr 410.16Cr 158.54Cr 2.07TCr 160.61Cr 157.1Cr 6.6TCr
Net Debt 211.22Cr 181.65Cr 170.85Cr 155.96Cr 291.69Cr 20TCr 292.63Cr 2.03TCr 783.03Cr 10TCr 793.23Cr 775.89Cr 33TCr 163.07Cr 140.24Cr 131.9Cr 120.41Cr 225.19Cr 15TCr 225.92Cr 1.56TCr 604.51Cr 7.9TCr 612.39Cr 599Cr 25TCr
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change
08/26/08 253.80 +2.59%
07/26/07 €247.40 -1.59%
04/26/04 €251.40 +0.36%
03/26/03 €250.50 +2.92%
02/26/02 €243.40 -1.74%
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
288.50USD
Average target price
281.00USD
Spread / Average Target
-2.60%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!